European Biotech Acquisition EBIT

The latest EBIT for EBAC is $-2.8M as of December 2022. That compares with $-1.1M in the prior-year period — down 156.2% year over year. That is above the sector sector average of $-6.4M. Investors often review this figure alongside European Biotech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, EBAC's EBIT moved from $-1.1M to $-2.8M — a 156.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in European Biotech Acquisition's operating scale or balance-sheet position.

Against its sector companies, EBAC currently prints $-2.8M for EBIT, while the sector average sits near $-6.4M. That is roughly 56.0% above the sector mean. Large gaps often invite a closer look at European Biotech Acquisition's growth, margins, and balance sheet.

A EBIT figure of $-2.8M for EBAC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting EBAC's EBIT ($-2.8M), review year-over-year change from $-1.1M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.